Olaparib approved for 800 prostate and breast cancer patients in England
Olaparib (Lynparza), a targeted cancer drug, has been approved for hundreds of patients with certain breast cancers and prostate cancers in England.
Apr 11, 2023
0
22
Olaparib (Lynparza), a targeted cancer drug, has been approved for hundreds of patients with certain breast cancers and prostate cancers in England.
Apr 11, 2023
0
22
Mutations in our genes can lead to severe problems, like colon or liver cancer. But cancer is very complex. Mutations in the same genes can lead to different subtypes of tumors in different people. Currently, scientists don't ...
Apr 10, 2023
0
85
Second only to the notorious TP53 gene, the genes for assemblages known as mSWI/SNF protein complexes are the most frequently mutated entities in cancer cells. Made up of 10 to 15 subunits, the complexes are built from the ...
Apr 10, 2023
0
7
A new chip that holds different cell types in tiny, interconnected chambers could allow scientists to better understand the physiological and disease interactions between organs. The integrated-gut-liver-on-a-chip (iGLC) ...
Apr 7, 2023
0
51
Understanding how cancer develops is critical for designing effective, personalized cancer therapies. Researchers have known for years that cancer begins with mutations in certain types of genes. One of these types of cancer ...
Apr 6, 2023
0
44
The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict—before treatment begins—how well ...
Apr 6, 2023
0
84
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) and lung cancer can have disruptive mutations in TP53 and/or CDKN2A tumor suppressor genes, which are associated with poor patient survival.
Apr 5, 2023
0
7
Lifestyle behaviors such as eating well and exercising can be significant factors in one's overall health. But the risk of developing cancer is predominantly at the whim of an individual's genetics.
Apr 4, 2023
0
42
Prostate cancer tumors harboring BRCA1/2 mutations are exceptionally sensitive to PARP inhibitors, while genomic alterations in other DNA damage response (DDR) genes are less responsive. To identify previously unknown genes ...
Apr 4, 2023
0
4
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma ...
Apr 3, 2023
0
21